Search results
Results From The WOW.Com Content Network
Dextroamphetamine (INN:dexamfetamine) is a potent central nervous system (CNS) stimulant and enantiomer [note 1] of amphetamine that is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and the negative symptoms of schizophrenia.
Current ISO 3166 country codes. The sortable table below contains the three sets of ISO 3166-1 country codes for each of its 249 countries, links to the ISO 3166-2 country subdivision codes, and the Internet country code top-level domains (ccTLD) which are based on the ISO 3166-1 alpha-2 standard with the few exceptions noted. See the ISO 3166 ...
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [15]
In the debut episode of “Distractible,” the guys discuss all things hair-related — including talking about the dangers of hair removal and imagining a sci-fi world in which an elite class ...
Call live aol support at. 1-800-358-4860. Get live expert help with your AOL needs—from email and passwords, technical questions, mobile email and more.
Adderall and Mydayis [10] are trade names [note 2] for a combination drug containing four salts of amphetamine.The mixture is composed of equal parts racemic amphetamine and dextroamphetamine, which produces a (3:1) ratio between dextroamphetamine and levoamphetamine, the two enantiomers of amphetamine. [12]
The "4-Digit Diagnostic Code" allows for mid-range gradations in growth deficiency (between the 3rd and 10th percentiles) and severe growth deficiency at or below the 3rd percentile. [71] Growth deficiency (at severe, moderate, or mild levels) contributes to diagnoses of FAS and pFAS, but not ARND or static encephalopathy.
The DSM-5 allows for diagnosis of the predominantly inattentive presentations of ADHD (ICD-10 code F90.0) if the individual presents six or more (five for adults) of the following symptoms of inattention for at least six months to a point that is disruptive and inappropriate for developmental level: